China Proposes Revising Export Control Catalog, Adding 40 AI and Tech Items
On.cc · 3 SOURCESabout 2 hours ago2 MIN
Summary
China's Ministry of Commerce and Ministry of Science and Technology on Friday (October 16) jointly announced a proposed revision to the "Catalog of Prohibited and Restricted Export Technologies in China," adding items in artificial intelligence, biomedicine, and photovoltaics. The public consultation runs until November 15, with a temporary registration management system for related technologies now in effect.
Key Points
- The revision covers 40 technologies across three domains: 23 in AI, 5 in biomedicine, and 12 in photovoltaics
- Of these, 14 technologies are proposed for prohibition and 26 for restriction
- AI technologies include large language models, AI agents, computing clusters, and information processing
- Biomedicine covers cell and gene therapy, small nucleic acid drugs, and pathogenic microorganisms
- Photovoltaics includes polysilicon manufacturing, wafer manufacturing, and battery manufacturing, including key equipment
- Registration applies to technology ownership transfers abroad, licensing of domestic technology to foreign entities, and changes in ownership or control to foreign parties
Why It Matters
The move signals China's intensified efforts to maintain technological security amid fierce global AI competition, while attempting to balance security concerns with continued international cooperation. Hong Kong technology firms engaged in cross-border technology transfers will need to navigate the new registration requirements, potentially affecting collaboration with mainland partners in AI and biotech sectors .
The move signals China's intensified efforts to maintain technological security amid fierce global AI competition, while attempting to balance security concerns with continued international cooperation. Hong Kong technology firms engaged in cross-border technology transfers will need to navigate the new registration requirements, potentially affecting collaboration with mainland partners in AI and biotech sectors .